Abstract: Nonwoven fabrics including a first outermost spunbond layer, a second outermost spunbond layer, and at least a first meltblown and/or melt-fibrillated layer disposed directly or indirectly between the first outermost spunbond layer and the second outermost spunbond layer. The first outermost spunbond layer comprises a first plurality of continuous fibers that are thermally fused and compacted against one another and define a microporous film on an outermost surface of the nonwoven fabric. The first plurality of continuous fibers comprises a first polymeric composition having a first melting point and the first meltblown layer and/or melt-fibrillated layer comprises a first plurality of meltblown fibers and/or melt-fibrillated fibers comprising a third polymeric composition having a third melting point, in which the first melting point is lower than the third melting point.

Abstract: The disclosure generally relates to binding proteins that comprise antigen binding sites, a T cell receptor binding site, and a T cell co-stimulatory molecule binding site. The disclosure also relates to pharmaceutical compositions comprising such binding proteins, nucleic acid molecules encoding such binding proteins, and vectors comprising such nucleic acid molecules. The disclosure further relates to methods of treating a disorder or condition using such binding proteins and pharmaceutical compositions, binding proteins and pharmaceutical compositions for use in the treatment of a disorder or condition, and the use of such binding proteins and pharmaceutical compositions for the manufacture of a medicament for treating a disorder or condition.

Abstract: The present disclosure relates to extracellular vesicles comprising one or more antigens from a coronavirus (e.g., SARS-CoV-1 or SARS-CoV-2) and optionally an adjuvant. Also provided herein are methods for producing the EVs and methods for using the EVs to treat and/or prevent diseases or disorders, e.g., infectious diseases.

Abstract: The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) via competitive binding to SARS-COV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-COV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 ?M, and low cytotoxicity, making it promising for clinical use. While established SARS-COV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.

Abstract: Techniques are described herein that are capable of registering a user device with a cloud-based management service using an intermediate cloud storage. For instance, the intermediate cloud storage may store an encrypted data blob including information that identifies the user device. The intermediate cloud storage or a registration system may decrypt the encrypted data blob so that the registration system may use the decrypted data blob to register the user device with the cloud-based management service. For instance, the registration system may retrieve the encrypted or decrypted data blob from the intermediate cloud storage by providing a requisite secret to the intermediate cloud storage. The requisite secret may be provided to the registration system by the user device (e.g., via a matrix barcode, such as a QR code).

Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA-targeting systems comprising a novel DNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA. Methods for making and using and uses of such systems, methods, and compositions and products from such methods and uses are also disclosed and claimed.

Abstract: The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.

Abstract: Systems and methods for four-dimensional CT scan are provided. The methods may include determining a first region of a subject and a second region. A movement of the subject may occur within the second region. The methods may further include generating a first image set by performing, based on a first operation parameter corresponding to a first scan, the first scan on the first region of the subject, and generating a second image set by performing, based on a second operation parameter corresponding to a second scan, the second scan on a second region of the subject. The methods may further include obtaining movement information corresponding to the movement of the subject and determining a final image set based on the first image set, the movement information, and the second image set.

Abstract: RNA editing tools for use in systems designed to measure RNA in vivo and manipulate specific cell types are disclosed herein. An RNA sensor system comprising a) a single-stranded RNA (ssRNA) sensor comprising a stop codon and a payload; optionally wherein the ssRNA sensor further comprises a normalizing gene; and b) an adenosine deaminase acting on RNA (ADAR) deaminase; wherein the sensor is capable of binding to a ssRNA target to form a double-stranded RNA (dsRNA) duplex that becomes a substrate for the ADAR deaminase; wherein the substrate comprises a mispairing within the stop codon; and wherein the mispairing is editable by the ADAR deaminase, which editing can effectively remove the stop codon so as to enable translation and expression of the payload. A method of quantifying ribonucleic acid (RNA) levels using the RNA sensor system is also disclosed.

Abstract: A system can receive user data from a computing device of a user. Based on the user data, the system can determine that the user will utilize a transport service to arrive at a destination location at a specified time. Prior to the specified time, the system can monitor transport service conditions within a region that includes a current location of the user, and determine a service request time for the user based at least in part on the transport service conditions. The system then automatically generates the service request for the user at the service request time to match the user to a transport provider.

Abstract: An IV catheter system may have a catheter component with a catheter hub, a cannula extending distally from the catheter hub, and a push feature protruding outwardly from the catheter hub. The IV catheter system may also have a needle component with a needle hub, a needle extending distally from the needle hub along an axis, and a grip extending from the needle hub, generally parallel to the axis, with a pull feature. In the insertion configuration, the needle may be positioned within the cannula and the distal end of the needle hub may be seated in a needle port of the catheter hub. In the fluid delivery configuration, the needle may be positioned outside the catheter hub. The push and pull features may be positioned to facilitate manipulation with a single hand to move the IV catheter system from an insertion configuration to a fluid delivery configuration.

Abstract: A substrate processing apparatus includes an upper chamber space, a lower chamber space, a susceptor, and a flow control ring assembly comprising a seal ring and a flow control ring having a shape to surround the susceptor, the flow control ring assembly sealing or substantially sealing the upper chamber space from the lower chamber space while the susceptor in a first position.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for speech synthesis. The methods, systems, and apparatus include actions of obtaining an audio representation of speech of a target speaker, obtaining input text for which speech is to be synthesized in a voice of the target speaker, generating a speaker vector by providing the audio representation to a speaker encoder engine that is trained to distinguish speakers from one another, generating an audio representation of the input text spoken in the voice of the target speaker by providing the input text and the speaker vector to a spectrogram generation engine that is trained using voices of reference speakers to generate audio representations, and providing the audio representation of the input text spoken in the voice of the target speaker for output.

Abstract: Techniques are disclosed relating to eviction control for cache lines that store register data. In some embodiments, memory hierarchy circuitry is configured to provide memory backing for register operand data in one or more cache circuits. Lock circuitry may control a first set of lock indicators for a set of registers for a first thread, including to assert one or more lock indicators for registers that are indicated, by decode circuitry, as being utilized by decoded instructions of the first thread. The lock circuitry may preserve register operand data in the one or more cache circuits, including to prevent eviction of a given cache line from a cache circuit based on an asserted lock indicator. The lock circuitry may clear the first set of lock indicators in response to a reset event. Disclosed techniques may advantageously retain relevant register information in the cache with limited control circuit area.

Abstract: The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via competitive binding to SARS-CoV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-CoV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 ?M, and low cytotoxicity, making it promising for clinical use. While established SARS-CoV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.

Abstract: An accessory device includes multiple walls and textile layers covers the walls. The textile layers may be of the same materials. However, one of the textile layers may include a film that provides protections against stains and fraying. The textile layers may come together at a seam. Accessory devices may include a shell that includes a pocket used to seat the textile layers in order to form the seam. An additional seam may be formed by two ends of a textile layer. The additional seam may be supported by a reinforcement layer, and may also align with an opening formed in the accessory device.

Abstract: A system includes a housing and a first circuit board positioned inside the housing. The housing has a top panel, a bottom panel, a left side panel, a right side panel, a front panel, and a rear panel. The front panel is at an angle relative to the bottom panel in which the angle is in a range from 30 to 150°. The first circuit board has a length, a width, and a thickness, in which the length is at least twice the thickness, the width is at least twice the thickness, and the first circuit board has a first surface defined by the length and the width. The first surface of the first circuit board is at a first angle relative to the bottom panel in which the first angle is in a range from 30 to 150°. The first surface of the first circuit board is substantially parallel to the front panel or at a second angle relative to the front panel in which the second angle is less than 60°.

Abstract: A method for training a non-autoregressive TTS model includes obtaining a sequence representation of an encoded text sequence concatenated with a variational embedding. The method also includes using a duration model network to predict a phoneme duration for each phoneme represented by the encoded text sequence. Based on the predicted phoneme durations, the method also includes learning an interval representation and an auxiliary attention context representation. The method also includes upsampling, using the interval representation and the auxiliary attention context representation, the sequence representation into an upsampled output specifying a number of frames. The method also includes generating, based on the upsampled output, one or more predicted mel-frequency spectrogram sequences for the encoded text sequence.

Abstract: In various examples, feature location identification for autonomous and semi-autonomous systems and applications is described herein. Systems and methods are disclosed that use LiDAR data to determine locations of road markings within an environment. For instance, the LiDAR data may be used to generate one or more images, such as a top-down image, birds-eye-view (BEV) image, and/or an intensity image, representing the environment. The image(s) may then be processed using one or more machine learning models that are configured to determine information associated with the road markings, such as bounding shapes (e.g., bounding boxes) indicating the locations of the road markings within the image(s), classifications associated with the road markings (e.g., the types of road markings), and/or any other information. The information may then be used to perform one or more processes, such as updating a map of the environment and/or navigating a vehicle within the environment.

Abstract: In various examples, multimodal image data may be used to generate a set of top-down tile images, which are applied to a deep neural network generator architecture model to produce lane marking-specific heatmap images corresponding to the set of top-down tile images. The multimodal sensor data may include LIDAR-captured intensity channel data, LIDAR-captured feature height channel data, and optical color image channel data. The set of top-down tile images may be processed by the generator model to automatically detect lane boundaries and navigation boundaries to generate pixel-level heatmap images that may classify lane markings by marking characteristics such as line type and/or color. The generator model may comprise an encoder-decoder architecture, with multiscale feature extraction and/or context extraction functional layers intervening between the encoder model and the decoder model.